We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

Promethera Biosciences Announces CFO

Rectangle Image
News

Promethera Biosciences Announces CFO

Read time:
 

Promethera® Biosciences has announced that Frank Hazevoets has joined the company to lead its finance and administration team. Frank joined Promethera Biosciences SA on May 1, 2014 as chief financial officer (CFO). He will be based at the head office in Mont-Saint-Guibert, Belgium.

Frank Hazevoets is a highly experienced senior financial executive with over twenty five years international business experience. He trained at the Catholic University of Leuven (KUL) in Belgium as a commercial engineer and also obtained a masters degree in Artificial Intelligence and Cognitive Science.

He has worked in leading positions in corporate finance and investment banking, strategy and business development. During his six years as CFO at Tigenix, he supported the company in its funding and growth strategy and helped them to obtain the first European marketing authorization for cell-based medicinal products in Europe.

“We are delighted that Frank is joining Promethera Biosciences as CFO,” said Eric Halioua, chief executive officer. “He is going to play a key role in assisting our future development. Frank Hazevoets has the experience and expertise to strengthen the management team and to prepare the next strategic options at Promethera Biosciences. He will build the finance department to further support the future growth of Promethera®.”

“I am really looking forward to working with the experienced team at Promethera and to sharing my expertise with them,” said Frank Hazevoets, chief financial officer of Promethera Biosciences.

Hazevoets continued, “This company has the potential to become one of the leading orphan drug companies in the world. Many patients will benefit from their lead in developing and commercializing innovative cell and orphan therapy products based on proprietary technologies.”

Advertisement